{"entity":{"id":"david-gershenson","kind":"person","name":"David M. Gershenson","aka":[],"tldr":"Houston gynaecologic oncologist who defined low-grade serous ovarian cancer as a distinct disease and led GOG 281, the trial that showed the MEK inhibitor trametinib works better than standard treatments for it.","summary":"David Gershenson is a gynaecologic oncologist at MD Anderson Cancer Center whose work established low-grade serous carcinoma of the ovary as a separate, relatively chemotherapy-resistant disease. He was first author of the 2017 Journal of Clinical Oncology study of hormonal maintenance therapy after primary treatment and of the 2022 Lancet report of GOG 281/LOGS, in which trametinib lengthened progression-free survival compared with standard-of-care options in recurrent low-grade serous carcinoma. He has also led studies of rare ovarian germ cell and sex cord-stromal tumours.","asOf":"2026-09-18","links":[],"tags":["ovarian","gynaecological","trialist"],"related":[],"cancers":["low-grade-serous-ovarian-cancer","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022","paper-gershenson-hormonal-maintenance-lgsoc-jco-2017"],"journals":[],"dependsOn":[],"notes":[],"role":"Gynaecologic oncologist, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Low-grade serous ovarian cancer","Rare ovarian tumours","Hormonal and MEK-directed therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gershenson%5BAuthor%5D"}],"papers":[],"orcid":"0000-0001-9712-2140"},"route":"/people/david-gershenson/","neighbours":{"cancer":[{"id":"low-grade-serous-ovarian-cancer","kind":"cancer","name":"Low-grade serous ovarian cancer","route":"/cancers/low-grade-serous-ovarian-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"paper":[{"id":"paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022","kind":"paper","name":"GOG 281/LOGS: trametinib versus standard of care in recurrent low-grade serous ovarian cancer","route":"/key-papers/paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022/"},{"id":"paper-gershenson-hormonal-maintenance-lgsoc-jco-2017","kind":"paper","name":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","route":"/key-papers/paper-gershenson-hormonal-maintenance-lgsoc-jco-2017/"}]}}